NewAmsterdam Pharma assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis assumed coverage of NewAmsterdam Pharma (NAMS) with a Buy rating and $52 price target NewAmsterdam is a late clinical-stage biopharmaceutical company developing obicetrapib, a non-statin, next-generation cholesterol ester transfer protein small molecule inhibitor for low-density lipoprotein cholesterol reduction, the analyst tells investors in a research note. The firm says obicetrapib is :poised to burst into the lipid-lowering space.”